HYPERTENSION Flashcards
This trial compared the effects of different target blood pressure levels on cardiovascular outcomes in patients with hypertension. This demonstrated that lower blood pressure targets significantly reduced the risk of cardiovascular events in hypertensive patients, supporting the use of aggressive blood pressure control to improve outcomes.
Hypertension Optimal Treatment (HOT) (1998)
This trial compared the effects of different classes of antihypertensive medications on cardiovascular outcomes in patients with hypertension. This trial found that thiazide diuretics were as effective as other antihypertensive agents in reducing cardiovascular events and were more cost-effective, supporting their use as first-line therapy for hypertension.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
This trial evaluated the efficacy of antihypertensive treatment in reducing cardiovascular events in older adults with isolated systolic hypertension. This trial demonstrated that antihypertensive therapy significantly reduced the risk of stroke and coronary events in elderly patients with elevated systolic blood pressure.
Systolic Hypertension in the Elderly Program (SHEP) (1991)
This trial compared the efficacy of valsartan, an angiotensin II receptor blocker (ARB), versus amlodipine, a calcium channel blocker, in reducing cardiovascular events in patients with hypertension. This trial found no significant difference in cardiovascular outcomes between the two treatment groups, providing evidence for the comparable effectiveness of ARBs and calcium channel blockers in hypertension management.
Valsartan Antihypertensive Long-term Use Evaluation (VALUE) (2004)
This trial compared the effects of losartan, an angiotensin II receptor blocker (ARB), versus atenolol, a beta-blocker, on cardiovascular outcomes in patients with hypertension and left ventricular hypertrophy. This trial demonstrated that losartan was more effective than atenolol in reducing the risk of stroke and cardiovascular events in hypertensive patients with left ventricular hypertrophy.
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) (2002)
This trial compared the effects of amlodipine, a calcium channel blocker, with atenolol, a beta-blocker, on cardiovascular outcomes in patients with hypertension. This trial demonstrated that amlodipine-based therapy was more effective than atenolol-based therapy in reducing the risk of cardiovascular events, highlighting the importance of calcium channel blockers in hypertension management.
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) (2005)
This trial compared the effects of combination therapy with benazepril plus amlodipine versus benazepril plus hydrochlorothiazide in patients with hypertension. This trial demonstrated that the benazepril-amlodipine combination was more effective than the benazepril-hydrochlorothiazide combination in reducing cardiovascular events, emphasizing the benefits of combination therapy in hypertension management.
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) (2008)
This trial compared the effects of telmisartan, an angiotensin II receptor blocker (ARB), versus ramipril, an angiotensin-converting enzyme (ACE) inhibitor, versus their combination on cardiovascular outcomes in patients at high risk for cardiovascular events. This trial found no significant difference in cardiovascular outcomes between telmisartan and ramipril but observed more adverse events with the combination therapy.
Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (2008)
This trial investigated the efficacy of olmesartan, an angiotensin II receptor blocker (ARB), in preventing microalbuminuria in patients with type 2 diabetes and normoalbuminuria. ROADMAP demonstrated that olmesartan significantly reduced the risk of new-onset microalbuminuria in diabetic patients, highlighting the renoprotective effects of ARBs in diabetes management.
Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) (2008)
This trial compared the effects of intensive versus standard blood pressure control in patients with hypertension at high cardiovascular risk but without diabetes. This trial found that intensive blood pressure control significantly reduced the risk of cardiovascular events and mortality compared to standard control, supporting more aggressive blood pressure targets in high-risk hypertensive patients.
Systolic Blood Pressure Intervention Trial (SPRINT) (2015)
This trial investigated the effects of intensive blood pressure control on cognitive function and dementia risk in older adults with hypertension. This trial demonstrated that intensive blood pressure control significantly reduced the risk of mild cognitive impairment and probable dementia, highlighting the potential cognitive benefits of aggressive blood pressure management.
Systolic Blood Pressure Intervention Trial Memory and Cognition in Decreased Hypertension (SPRINT MIND) (2019)
This trial evaluated the effects of antihypertensive treatment in reducing cardiovascular events in patients aged 80 years and older with hypertension. HYVET demonstrated that antihypertensive therapy significantly reduced the risk of stroke and mortality in the very elderly, challenging the notion that hypertension should be undertreated in this population.
Hypertension in the Very Elderly Trial (HYVET) (2008)
This trial investigated the effects of ramipril, an angiotensin-converting enzyme (ACE) inhibitor, on cardiovascular outcomes in patients at high risk for cardiovascular events, including those with hypertension. This trial demonstrated that ramipril significantly reduced the risk of myocardial infarction, stroke, and cardiovascular mortality, supporting the use of ACE inhibitors in high-risk populations.
Heart Outcomes Prevention Evaluation (HOPE) (2000)
This trial evaluated the effects of amlodipine, a calcium channel blocker, on cardiovascular outcomes in patients at high risk for cardiovascular events, including those with hypertension. This trial demonstrated that amlodipine significantly reduced the risk of major cardiovascular events, supporting its use in high-risk populations for cardiovascular protection.
Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) (2003)
This trial compared the effects of telmisartan, an angiotensin II receptor blocker (ARB), versus ramipril, an angiotensin-converting enzyme (ACE) inhibitor, versus their combination on cardiovascular outcomes in patients at high risk for cardiovascular events, including those with hypertension. This trial found no significant difference in cardiovascular outcomes between telmisartan and ramipril but observed more adverse events with the combination therapy.
Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (2008)
